Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Endocrine 1CNS 1

Conditions

Brain Neoplasms 276Glioblastoma 250Glioma 156Astrocytoma 99Central Nervous System Neoplasms 70Gliosarcoma 69Oligodendroglioma 63Neuroblastoma 63Neoplasms 52Breast Neoplasms 44Melanoma 42Carcinoma, Non-Small-Cell Lung 38Neoplasm Metastasis 33Medulloblastoma 30Lymphoma 29Recurrence 28Lung Neoplasms 27Ependymoma 24Sarcoma 20Ovarian Neoplasms 19Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Meningioma 18Lymphoma, Non-Hodgkin 18Leukemia 18Meningeal Carcinomatosis 17Burkitt Lymphoma 17Multiple Myeloma 16Lymphoma, Large B-Cell, Diffuse 16Diffuse Intrinsic Pontine Glioma 15

Interventions

Dexamethasone 1Calcium Dobesilate 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adenoma, Acidophil × CNS × Clear all
NCT01088763 2014-11-05

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
129 enrolled
CNSEndocrineLymphoidOther hematologic neoplasmSarcoma

Familial ependymoma, Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Astrocytoma, Burkitt Lymphoma, Medulloblastoma, Oligodendroglioma, Pituitary Neoplasms, Recurrence, Spinal Cord Neoplasms, Prolactinoma, Choroid Plexus Neoplasms, Lymphoma, Large-Cell, Anaplastic, Rhabdoid Tumor, Optic Nerve Glioma, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡